Literature DB >> 15302492

Screening for ischemic heart disease in patients with erectile dysfunction: role of penile Doppler ultrasonography.

Ahmed I El-Sakka1, Ayman M Morsy.   

Abstract

OBJECTIVES: To assess the role of measuring cavernosal artery blood flow as a screening tool for ischemic heart disease in patients with erectile dysfunction (ED).
METHODS: A total of 303 male patients with ED were enrolled in this study. Patients were interviewed for ED using the International Index of Erectile Function. The penile vasculature was assessed using color Doppler ultrasonography and the Digital Inflection Rigidometer. All patients were referred to a cardiologist for evaluation of ischemic heart disease (IHD). All patients underwent routine laboratory investigations, plus total testosterone and prolactin assessments.
RESULTS: Seventy-six percent of the patients had organic causes of ED. Of the 303 patients, 31.4% had different degrees of IHD. A statistically significant association was found between the presence of IHD and arteriogenic causes of ED, a poor response to intracorporal injection, poor rigidity in the Digital Inflection Rigidometer, and low peak systolic velocity (PSV) in the cavernosal arteries (P <0.05 for each). No statistically significant association was found between the presence of IHD and increasing end-diastolic velocity values or decreasing resistive index in the cavernosal arteries (P >0.05 for each). A statistically significant association was found between a higher grade of IHD and a decreasing PSV value (P <0.05).
CONCLUSIONS: The results of this study established that a reduced PSV of the cavernous artery is associated with IHD. Determining the PSV could be a reliable screening tool for the detection of IHD in patients with ED.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15302492     DOI: 10.1016/j.urology.2004.03.016

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  6 in total

Review 1.  Should patients with erectile dysfunction be evaluated for cardiovascular disease?

Authors:  Kenneth A Ewane; Hao-Cheng Lin; Run Wang
Journal:  Asian J Androl       Date:  2011-11-28       Impact factor: 3.285

Review 2.  Urological aspects of the metabolic syndrome.

Authors:  Jan Hammarsten; Ralph Peeker
Journal:  Nat Rev Urol       Date:  2011-08-02       Impact factor: 14.432

Review 3.  [Chronic PDE-5 inhibition in patients with erectile dysfunction: new treatment approach using once daily Tadalafil].

Authors:  H Porst; K Hell-Momeni; H Büttner
Journal:  Urologe A       Date:  2009-11       Impact factor: 0.639

4.  Subclinical Vascular Disease and Subsequent Erectile Dysfunction: The Multiethnic Study of Atherosclerosis (MESA).

Authors:  David I Feldman; Miguel Cainzos-Achirica; Kevin L Billups; Andrew P DeFilippis; Kanchan Chitaley; Philip Greenland; James H Stein; Matthew J Budoff; Zeina Dardari; Martin Miner; Roger S Blumenthal; Khurram Nasir; Michael J Blaha
Journal:  Clin Cardiol       Date:  2016-05-03       Impact factor: 2.882

Review 5.  Erectile dysfunction in Arab countries. Part II: Diagnosis and treatment.

Authors:  Ahmed I El-Sakka
Journal:  Arab J Urol       Date:  2012-03-15

Review 6.  Erectile dysfunction in Arab countries. Part I: Prevalence and correlates.

Authors:  Ahmed I El-Sakka
Journal:  Arab J Urol       Date:  2012-02-28
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.